论文部分内容阅读
目的评估聚乙二醇干扰素α-2a与拉米夫定治疗HBeAg阳性慢性乙型肝炎的成本效果。方法运用相关文献资料和Delphi专家咨询数据,采用Markov模型对聚乙二醇干扰素α-2a与拉米夫定治疗慢性乙型肝炎疗效进行经济学评价。结果与使用拉米夫定1～4年比较,使用聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者1年,人均延长寿命0.52～0.79年,每延长1年寿命所需增加的医疗费用为16563～18954元。结论使用聚乙二醇干扰素α-2a 1年相比于使用拉米夫定1～4年治疗HBeAg阳性慢性乙型肝炎具有更好的成本效果。
Objective To evaluate the cost-effectiveness of peginterferon alfa-2a and lamivudine in the treatment of HBeAg-positive chronic hepatitis B. Methods Using the relevant literature and Delphi expert consultation data, the Markov model was used to evaluate the efficacy of pegylated interferon α-2a and lamivudine in the treatment of chronic hepatitis B. Results Compared with 1 to 4 years after lamivudine treatment, peginterferon alfa-2a treatment of HBeAg-positive chronic hepatitis B patients for 1 year, the average life expectancy 0.52 ~ 0.79 years, every 1-year extension of life expectancy increased The medical expenses for 16563 ~ 18954 yuan. Conclusions The use of pegylated interferon alpha-2a for 1 year has a better cost-effectiveness compared to 1 to 4 years of lamivudine for the treatment of HBeAg-positive chronic hepatitis B.